Alzamend Neuro, Inc. ALZN
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -45.71% | -94.30% | -66.60% | 1.27% | 15.57% |
| Total Depreciation and Amortization | 68.39% | 118.11% | 88.58% | 59.06% | 29.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 158.65% | 111.51% | -50.78% | -46.20% | -57.67% |
| Change in Net Operating Assets | 170.58% | 95.34% | 123.72% | 94.58% | -410.81% |
| Cash from Operations | 13.10% | -22.83% | 18.44% | 28.65% | -30.65% |
| Capital Expenditure | -- | -- | -133.33% | -133.33% | -133.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -133.33% | -133.33% | -133.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -45.87% | -70.61% | -60.54% | -36.46% | 115.94% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -25.06% | -47.84% | -41.75% | -49.04% | 141.35% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -29.56% | -53.74% | -47.24% | -47.78% | 122.79% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -55.49% | -190.63% | -120.97% | -90.85% | 982.91% |